Investor Presentation Q1 2018

Investor Presentation First three months of 2018 VictozaⓇ accounts for 22% of total sales in first three months of 2018 Slide 99 Reported currencies Sales Q1 2018 (mDKK) Sales split Sales full year 2017 (mDKK) Sales split TresibaⓇ 1,755 7% 7,327 7% LevemirⓇ 2,780 10% 14,118 13% NovoRapidⓇ 4,695 17% 20,025 18% NovoMix® 2,501 9% 10,257 9% VictozaⓇ 5,989 22% 23,173 21% SaxendaⓇ 770 3% 2,562 2% Diabetes care and Obesity¹ 22,608 84% 92,877 83% NovoSevenⓇ 2,154 8% 9,206 8% NorditropinⓇ 1,481 5% 6,655 6% Biopharmaceuticals¹ 4,322 16% 18,819 17% Total¹ 26,930 100% 111,696 100% 1 Values are higher than the sum of the total elements listed due to residual values from products not listed changing diabetes® novo nordisk

View entire presentation